Get the Stockscreener App
2.18
1.79%
-0.05
Annovis Bio Inc stock is traded at $2.18, with a volume of 153.99K.
It is down -1.79% in the last 24 hours and down -58.05% over the past month.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
See More
Previous Close:
$2.23
Open:
$2.25
24h Volume:
153.99K
Relative Volume:
0.34
Market Cap:
$43.45M
Revenue:
-
Net Income/Loss:
$-40.94M
P/E Ratio:
-0.5677
EPS:
-3.84
Net Cash Flow:
$-22.97M
1W Performance:
-19.78%
1M Performance:
-58.05%
6M Performance:
-77.21%
1Y Performance:
-78.49%
1-Day Range:
$2.13
$2.2687
1-Week Range:
$2.08
$2.77
52-Week Range:
$2.08
$20.00
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.185 | 43.45M | 0 | -40.94M | -22.97M | -3.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.15 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.27 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.71 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.07 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
117.11 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-25-24 | Upgrade | Maxim Group | Hold → Buy |
| Dec-29-23 | Initiated | Canaccord Genuity | Buy |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments - MSN
Annovis Bio stock hits 52-week low at $2.42 amid market challenges - Investing.com
Annovis to Host Patients' Live Forum on February 27, 2025 - Quantisnow
Inside Annovis's Groundbreaking Alzheimer's Trial: CEO Opens Direct Dialogue With Patients - StockTitan
Annovis Bio stock hits 52-week low at $2.59 amid sharp decline - MSN
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight - GlobeNewswire Inc.
Annovis Bio stock rating cut to hold at D. Boral Capital - MSN
Annovis Bio stock hits 52-week low at $2.59 amid sharp decline By Investing.com - Investing.com South Africa
Annovis Bio CEO to Present at Oppenheimer Healthcare Life Sciences Conference - MSN
Annovis Bio Launches Phase 3 Trial for Alzheimer’s Drug Buntanetap - MSN
Annovis Bio begins pivotal phase 3 Alzheimer's drug trial - MSN
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Annovis Bio Raises $21 Million in Public Offering to Advance Alzheimer’s Research - MSN
Annovis Bio Inc. CEO to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference on Pivotal Phase 3 Trial Progress - Nasdaq
Annovis to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference - Hamilton Spectator
Annovis begins treatment of subjects in Alzheimer’s trial - Yahoo Finance
Annovis Bio begins pivotal phase 3 Alzheimer's drug trial By Investing.com - Investing.com Australia
Annovis Bio announces first patients entered Phase 3 study of buntanetap - Yahoo Finance
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease - GlobeNewswire
Annovis Bio stock hits 52-week low at $4.05 amid market challenges - MSN
Annovis Bio sets terms for $21 million public offering - MSN
Annovis Bio completes $21 million stock and warrant offering - MSN
Annovis Bio Enrolls First Patients in Phase 3 Trial of Buntanetap for Early Alzheimer's Disease - Marketscreener.com
Annovis Bio Launches Phase 3 Alzheimer’s Study - TipRanks
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease - Quantisnow
Annovis Bio completes $21 million stock and warrant offering By Investing.com - Investing.com South Africa
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering - GlobeNewswire
Alzheimer's Drug Developer Annovis Secures Critical $21M Funding for Final-Stage Trial - StockTitan
Annovis Bio stock dips after pricing $21M securities offering - MSN
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Annovis Bio Prices $21 Million Public Offering; Shares Fall Sharply -February 03, 2025 at 11:56 am EST - Marketscreener.com
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.12%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):